Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Phase 1 Completed 28 enrolled Tracon Pharmaceuticals Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.

Timeline

Start: 2008-06
Primary completion: 2010-06
Completion: 2010-09

Publications

Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):714-23. doi: 10.1007/s10637-012-9876-9. Epub 2012 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methoxyamine	Small molecule	15 mg/m2	Oral
Subject	Methoxyamine	Small molecule	30 mg/m2	Oral
Subject	Methoxyamine	Small molecule	60 mg/m2	Oral
Subject	Methoxyamine	Small molecule	100 mg/m2	Oral
Background	Pemetrexed	Small molecule	—	Intravenous

Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Summary

Timeline

Publications

Drugs

Indications